Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04296097
Other study ID # 38RC18.208
Secondary ID 2019-A01562-55
Status Recruiting
Phase N/A
First received
Last updated
Start date April 23, 2021
Est. completion date October 2026

Study information

Verified date May 2023
Source University Hospital, Grenoble
Contact Stéphan CHABARDES, MD, PhD
Phone 33 (0)4 76 76 93 85
Email SChabardes@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study aims at evaluating the effectiveness of the treatment of unilateral or bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep Brain Stimulation (DBS) of the parieto-insular right operculum 3 (OP3) in a cross-over, double study design.


Description:

Subjective, non-pulsatile, permanent, severe, tinnitus, refractory to all treatment are very disabling. They can lead to serious depression and suicidal behavior, which justifies the development of innovative therapeutic options. Current management is essentially based on psychological therapy and / or prosthetic, to improve for hearing loss that can be frequently associated. In fact, the main objective is habituation for these patients, but when the tinnitus is too intense, it is impossible. Three recent publications in functional magnetic resonance imaging (fMRI) have reported a novel physiopathological hypothesis to explain the appearance of subjective tinnitus. They highlight the prominent role of the right operculum 3 (OP3), a deep opercular region (parieto-insular junction) in the emergence of this symptom. The investigators hypothesize that inhibition of this region using high frequency stimulation could, significantly improve the intensity of the symptom and consequently their quality of life in this selected population.


Recruitment information / eligibility

Status Recruiting
Enrollment 7
Est. completion date October 2026
Est. primary completion date October 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Between 18 and 75 years old, 2. Uni or bilateral permanent non-pulsatile tinnitus, without associated vestibular pathology, with or without hearing loss, 3. Severe tinnitus resistant to treatment failure, 4. Tinnitus intensity on the Visual Analog Scale (VAS) = 7, 5. Presenting a quality of life score on the Tinnitus Handicap Inventory (THI) questionnaire> 76 (= grade 5), 6. Social security affiliates or beneficiaries of such a scheme 7. Informed and written consent signed by the patient. Exclusion Criteria: 1. Vestibular dysfunction (balance disorder), 2. Epilepsy, 3. Intercurrent serious pathology, 4. Brain tumor, 5. Contraindication to surgery or anesthesia, 6. History of cerebral infection with herpesvirus, 7. With a contraindication to the practice of MRI, MEG, Computerized Tomography (CT) scan, 8. Under anticoagulants and antiaggregants (Anti vitamin K, low molecular weight heparin, aspirin and derivatives, clopidogrel antiplatelet agents and assimilated, new oral anticoagulants (NACO)) for which a therapeutic window can not be opened within 3 months before and after the surgery, 9. Included in another therapeutic protocol, 10. Progressive dementia or psychiatric illness, 11. Presenting a suicidal risk deemed important for less than 3 months (Montgomery and Asberg depression scale (MADRS): suicidality item (item 10) score> 2), 12. Enforced hospitalisation, 13. Pregnant, parturient or breastfeeding, lack of contraception in patients with the capacity to procreate, 14. Subject to a legal protection measure, 15. Deprived of liberty by judicial or administrative decision, 16. Isolated patient without any contact in case of emergency.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DBS
Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)

Locations

Country Name City State
France CLINATEC Grenoble

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Grenoble Commissariat A L'energie Atomique, Équipe 5 Neuroimagerie et perfusion cérébrale, Grenoble Institut des Neurosciences (GIN)

Country where clinical trial is conducted

France, 

References & Publications (5)

Eickhoff SB, Grefkes C, Zilles K, Fink GR. The somatotopic organization of cytoarchitectonic areas on the human parietal operculum. Cereb Cortex. 2007 Aug;17(8):1800-11. doi: 10.1093/cercor/bhl090. Epub 2006 Oct 10. — View Citation

Job A, Jacob R, Pons Y, Raynal M, Kossowski M, Gauthier J, Lombard B, Delon-Martin C. Specific activation of operculum 3 (OP3) brain region during provoked tinnitus-related phantom auditory perceptions in humans. Brain Struct Funct. 2016 Mar;221(2):913-22. doi: 10.1007/s00429-014-0944-0. Epub 2014 Dec 12. — View Citation

Job A, Paucod JC, O'Beirne GA, Delon-Martin C. Cortical representation of tympanic membrane movements due to pressure variation: an fMRI study. Hum Brain Mapp. 2011 May;32(5):744-9. doi: 10.1002/hbm.21063. — View Citation

Job A, Pons Y, Lamalle L, Jaillard A, Buck K, Segebarth C, Delon-Martin C. Abnormal cortical sensorimotor activity during "Target" sound detection in subjects with acute acoustic trauma sequelae: an fMRI study. Brain Behav. 2012 Mar;2(2):187-99. doi: 10.1002/brb3.21. — View Citation

Maliia MD, Donos C, Barborica A, Popa I, Ciurea J, Cinatti S, Mindruta I. Functional mapping and effective connectivity of the human operculum. Cortex. 2018 Dec;109:303-321. doi: 10.1016/j.cortex.2018.08.024. Epub 2018 Sep 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness of the treatment using Deep Brain Stimulation (DBS) of the right operculum 3 (OP3). Difference in intensity of tinnitus Visual Analog Scale (VAS) [0/10 : higher scores mean better outcome] between the end and the beginning of each of the two periods of the crossover. 2.5 months
Secondary Incidence of DBS Treatment on Emergent Adverse Events (Tolerance) after surgical intervention and stimulation following the implantation of the DBS medical device. Emergent Adverse events (partial or general epileptic seizures, worsening of tinnitus, surgical complications, ...): 1) post-operative computed tomography (CT); 2) Clinical evaluation. 15 months
Secondary Evaluation of the subjective effect of stimulation on quality of life. Scores on the Tinnitus Handicap Inventory (THI) questionnaire [0/100 : higher scores mean worse outcome] at 6 months (early phase) and at 15 months compared to the preoperative THI of the same patient. 15 months
Secondary Evaluation of the subjective effect of stimulation on anxiety / depression. Scores on the Hospital Anxiety and Depression Scale (HAD) [0/21 : higher scores mean worse outcome] at 6 months (early phase) and at 15 months compared to preoperative HAD of the same patient. 15 months
Secondary Changes comparison of the connectivity of OP3 explored by functional Magnetic Resonance Imaging (fMRI) at 1.5 T. Functional Magnetic Resonance Imaging records (fMRI 1.5 T) performed preoperatively and at 15 months postoperatively. 15 months
Secondary Connectivities changes of the right OP3 measured by magnetoencephalography (MEG) at baseline 'preoperatively) and the post op (within 1 week) and at long term follow up (15 months) with active stimulation (ON) and inactive (OFF) during MEG recording. Magnetoencephalography (MEG) records at baseline (preoperatively) and the post op (within 1 week) and at long term follow up (15 months) with active stimulation (ON) and inactive (OFF) during MEG recording. 15 months
Secondary Characterization of the Local Field Potential (LFP) recorded and correlations with tinnitus features perceived by the patient, based on their intensity and characteristic. Local Field Potential (LFP) records on the electrode when the patient perceives tinnitus features 1) intraoperatively 2) before the implantation of the stimulator. One week